Company Profile For Biota Holdings Limited

Biota Holdings Limited is an Australian company engaged in anti-infective drug discovery and development, and its commercialization, with key capabilities in respiratory diseases, particularly influenza. Biota has developed the in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Relenza is used to treat seasonal influenza. Biota’s research outcomes have included nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, the Company has a partnership with Daiichi Sankyo for the development of second-generation influenza anti-virals.

BRIEF: For the fiscal year ended 30 June 2009, Biota Holdings Limited's revenue increased 54% to A$60.6M. Net income totaled A$38.2M vs.loss of A$6.5M. Revenues reflects an increase in royalty income and higher partnering revenue. Net income also reflects an increase in other income, a decrease in product development expense, lower business development expense, decrease in finance cost and lower litigation expense.

Biota Holdings Limited
10/585 Blackburn Road
Notting Hill   VIC   3168
P: +613.99153700
F: +613.99153702

34